EKEfstratios Koutroumpakis

Efstratios Koutroumpakis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Efstratios Koutroumpakis has a total of 577 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiation Vasculopathy of the Coronary Arteries: State-of-the Art Review

    by Jeffrey Xia, Jean Kim, Abhishek Sharma, Benjamin Yang, Prasanna G. Alluri, Katelyn Atkins, Eric D. Miller, Terence M. Williams, Daniel Addison, Amit Arbune, et al.

    Radiation-associated coronary artery disease (RACAD) is a distinct form of coronary artery disease with several specific biological and clinical aspects as well as key knowledge gaps. RACAD is prevalent in patients with cardiac exposure to radiotherapy. As radiotherapy is integral to the effective treatment of many thoracic malignancies, improved long-term survivorship is coupled with increased risk for RACAD. Ionizing radiation induces free radical generation and activation of proinflammatory cascades, leading to endothelial dysfunction and accelerated atherosclerosis. Risks for RACAD are determined both by radiotherapy, including the radiation dose and the proximity of coronary arteries to the radiotherapy field, and by patient-specific factors, such as younger age, higher baseline cardiovascular risk, and concurrent cardiotoxic systemic therapies. Importantly, radiotherapy delivery is highly individualized on the basis of tumor location and treatment strategy, resulting in heterogeneous coronary exposure to radiation and patient-to-patient variability. Clinical presentation may occur early, within 1 to 2 years, especially in patients with higher cardiac radiation doses (eg, lung or esophageal cancer), or after a latency period of 5 to 20 years with lower cardiac dose radiation exposure (eg, left-sided breast cancer). Patients generally present with symptoms similar to conventional coronary artery disease. However, RACAD symptoms may be underrecognized in cancer survivors due to overlapping treatment-related fatigue, pulmonary disease, or competing oncologic symptoms. Diagnosis and management generally follow standard coronary artery disease guidelines while incorporating cancer-specific considerations, such as planned oncologic surgeries, bleeding risk, postradiotherapy complications such as atretic internal mammary arteries, and cardiotoxic effects of systemic cancer therapies. Primary prevention of RACAD is critical, emphasizing advances in precision radiotherapy, including delivery techniques with improved coronary dosimetry, and cardiac shielding. Key knowledge gaps include understanding long-term outcomes with contemporary 3-dimensional conformal radiotherapy techniques, validated cancer-specific risk prediction models on the basis of coronary dosimetry, optimal surveillance protocols, targeted molecular pharmacotherapies, and risk analysis of percutaneous versus surgical management of RACAD. Prospective studies are needed to develop cancer- and dosimetry-specific risk calculators, validating cardioprotective interventions, and improving multidisciplinary cardio-oncology collaboration to optimize early detection of RACAD and timely intervention in the growing population of cancer survivors.

  • Open Access

    Cardiometabolic health’s influence on the efficacy of pre-operative hormone therapy for men with localized high-risk prostate cancer

    by Mitchell Boshkos, Maria Julia Moura Nascimento Santos, Rebecca S. Tidwell, Neha Venkatesh, Sagar S. Mukhida, Patrick G. Pilie, Sumit K. Subudhi, Paul G. Corn, Ana M. Aparicio, Bilal A. Siddiqui, et al.

    Background Altered lipid metabolism, adiposity, and androgens have been linked to cardiac disease and prostate cancer. Adiposity increases risk of recurrence for prostate cancer and may enhance response to androgen receptor pathway inhibition (ARPI). We evaluated whether adiposity and circulating lipid metabolites are associated with response to pre-operative ADT + /- ARPI in localized high-risk prostate cancer (HRPCa). Methods We performed a post hoc analysis of 104 men with localized HRPCa treated with 3–6 months of preoperative ADT + /- ARPI across three trials. Body composition was quantified from L3 CT imaging at baseline and at radical prostatectomy (RP; end-of-treatment [EOT] n = 56). Plasma lipid metabolites were profiled by UPLC-MS at baseline (n = 60) and in paired baseline/EOT samples (n = 59). Pathologic response was defined as ≤ T2N0 at RP. PSA progression-free survival (PFS) was defined as time from RP to PSA ≥ 0.2 ng/mL or initiation of radiotherapy. Results Median age was 63 years, 76.9% had Gleason grade group 4-5, and 43.7% had clinical T3-4 disease. At RP, lower visceral (VATi, p = 0.002) and subcutaneous adiposity (SATi, p = 0.004) were associated with pathologic response. Increasing adiposity at RP was associated with PSA progression (per 10-unit increase: VATi HR 1.09, p = 0.04; SATi HR 1.14, p = 0.03). In paired analyses (n = 59), pathologic responders demonstrated decreases (p < 0.05) in diacylglycerols and polyunsaturated fatty acyl chain-containing triacylglycerols (PUFA-TAGs) and elevations in ceramide species. Non-responders exhibited increases (p < 0.05) in PUFA-TAGs and glycerophospholipids with reductions in lysophosphatidylcholine species, long-chain acylcarnitine, and cholesterol. Conclusions Higher post-treatment adiposity and intrapatient changes in lipid metabolite pathways were associated with inferior outcomes after pre-operative hormone therapy, supporting a stage-dependent link between cardiometabolic health and prostate cancer that warrants further elucidation.

  • LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis

    by Sivareddy Kotla, Jonghae Lee, Kyung Ae Ko, Weiqing Chen, Venkata Subrahmanya Kumar Samanthapudi, Oanh Hoang, Gilbert F. Mejia, Shengyu Li, Hani Lee, Aijun Zhang, et al.

    BACKGROUND: Atherothrombosis, which underlies most acute coronary syndromes and is driven by intraplaque thrombosis, preferentially occurs in regions of disturbed blood flow (d-flow). Although LATS1/2 (large tumor suppressor kinases 1 and 2) are known regulators of endothelial mechanotransduction, the mechanisms by which d-flow connects endothelial senescence, proliferation, and intraplaque thrombosis remain poorly understood. METHODS: We investigated endothelial cell (EC)-specific roles of Lats1/2 using inducible EC-specific knockout mice in a partial carotid ligation model. Spatial multiomics of human and mouse plaques was performed using imaging mass cytometry, COMET sequential immunofluorescence, and spatial metabolomics. RESULTS: Tamoxifen-induced deletion of both Lats1 and Lats2 (homozygous) in ECs caused fatal edema and increased vascular permeability. In contrast, Lats1 het ( ± ) / Lats2 homo ( −/−) -EC-specific knockout mice survived and developed spontaneous atherothrombotic plaques with neovascularization. Spatial proteomics revealed that LATS1/2 loss induced a senescence-associated stemness phenotype driven by CD38 upregulation. Spatial metabolomics showed sulfite and taurine accumulation, indicating SUOX (sulfite oxidase) deficiency. CD38 suppressed SUOX, demonstrated a switch into the reverse mode of mitochondrial complex V, increased succinate dehydrogenase activity, and promoted ATP consumption. Despite ATP depletion, glutamate metabolism and the citric acid cycle flux increased, sustaining EC proliferation under energetic stress. This senescence-associated stemness state promoted both proliferation and senescence, leading to fragile, leaky neovessels and intraplaque thrombotic lesions. Pharmacological CD38 inhibition attenuated these phenotypes. Similar EC states were observed in human plaques. CONCLUSIONS: Loss of Lats1/2 in ECs induces a CD38-associated senescence-associated stemness-like phenotype that promotes intraplaque thrombosis through mitochondrial metabolic reprogramming, including changes consistent with reverse-mode operation of mitochondrial complex V. These findings define a mechanistic link between disturbed flow, endothelial metabolic reprogramming, and intraplaque thrombosis and hemorrhage.


  • Open Access

    Integrating cardiometabolic health with AR pathway modulation and prostate cancer

    by Mitchell Boshkos, Maria Julia Moura Nascimento Santos, Rebecca Tidwell, Neha Venkatesh, Sagar Mukhida, Patrick Pilie, Sumit Subudhi, Paul Corn, Ana Aparicio, Bilal Siddiqui, et al.

    BACKGROUND: Altered lipid metabolism, adiposity, and androgens have been linked to cardiac disease and prostate cancer. Adiposity increases risk of recurrence for prostate cancer and may enhance response to androgen receptor pathway inhibition (ARPI). We evaluated whether adiposity and circulating lipid metabolites are associated with response to pre-operative ADT +/- ARPI in localized high-risk prostate cancer (HRPCa). METHODS: We performed a post hoc analysis of 104 men with localized HRPCa treated with 3–6 months of preoperative ADT +/- ARPI across three trials. Body composition was quantified from L3 CT imaging at baseline and at radical prostatectomy (RP; end-of-treatment [EOT] n=56). Plasma lipid metabolites were profiled by UPLC-MS at baseline (n=60) and in paired baseline/EOT samples (n=59). Pathologic response was defined as ≤ T2N0 at RP. PSA progression-free survival (PFS) was defined as time from RP to PSA ≥ 0.2 ng/mL or initiation of radiotherapy. RESULTS: Median age was 63 years, 76.9% had Gleason grade group 4-5, and 43.7% had clinical T3-4 disease. At RP, lower visceral (VATi, p=0.002) and subcutaneous adiposity (SATi, p=0.004) were associated with pathologic response. Increasing adiposity at RP was associated with PSA progression (per 10-unit increase: VATi HR 1.09, p=0.04; SATi HR 1.14, p=0.03). In paired analyses (n=59), pathologic responders demonstrated decreases (p<0.05) in diacylglycerols and polyunsaturated fatty acyl chain-containing triacylglycerols (PUFA-TAGs) and elevations in ceramide species. Non-responders exhibited (p<0.05) increases (p<0.05) in PUFA-TAGs and glycerophospholipids with reductions in lysophosphatidylcholine species, long-chain acylcarnitine, and cholesterol. CONCLUSIONS: Higher post-treatment adiposity and intrapatient changes in lipid metabolite pathways were associated with inferior outcomes after pre-operative hormone therapy, supporting a stage-dependent link between cardiometabolic health and prostate cancer that warrants further elucidation.

  • Top Cited Papers

    Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection

    by Jeremy A. Slivnick, Sze Chi Lim, Michael Randazzo, Mathew S. Maurer, Stephen Helmke, Marielle Scherrer-Crosbie, Azin Vakilpour, Karolina M. Zareba, Akash Goyal, Richard Cheng, et al.

    BACKGROUND: Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart failure in which timely diagnosis is essential to initiate life-prolonging therapies. While artificial intelligence (AI)-based tools using transthoracic echocardiography (TTE), electrocardiography, or electronic health records have demonstrated promise for CA detection, most rely on single data sources. We aimed to evaluate whether integrating clinical, laboratory, and TTE biomarkers improves the performance of an existing TTE-based AI model for CA detection. METHODS: We developed and tested a combined AI echo-clinical model (AI-ECM) incorporating demographics, laboratory biomarkers, and TTE parameters into a previously validated TTE-only AI model (Us2.Ca). Model training and internal validation were performed using the Amyloidosis Imaging International Consortium, a global multiethnic registry comprised of 727 patients with CA and 316 controls, including 202 with suspected transthyretin-CA with negative diagnostic evaluation and 114 patients with biopsy-proven extracardiac light chain amyloidosis without cardiac involvement. Ground truth CA diagnosis was adjudicated per consensus criteria. AI-ECM and Us2.Ca performance was assessed using area under the curve, accuracy, sensitivity, and specificity. RESULTS: In building the AI-ECM, feature importance analysis showed that having the Us2.Ca prediction scores, relative wall thickness, sex, and estimated glomerular filtration rate contributed most to performance. The AI-ECM demonstrated superior performance (area under the curve, 0.94; accuracy, 90%; sensitivity, 93%; specificity, 85%) compared with the Us2.Ca (area under the curve, 0.89; accuracy, 80%; sensitivity, 76%; specificity, 91%; P =0.006). While the Us2.Ca model classification was indeterminate in 9% of the cases, the AI-ECM allowed classification of all cases. The AI-ECM improved sensitivity for light chain-CA detection and maintained high accuracy across subtypes and control groups. CONCLUSIONS: A multiparametric AI model integrating basic clinical, laboratory, and TTE data with the deep learning Us2.Ca improved performance for CA detection over Us2.Ca alone. This approach represents a step toward scalable, AI-guided precision diagnostics for CA in diverse populations.


  • Open Access

    Colchicine Directly Targets Aldehyde Dehydrogenase 2 (ALDH2) to Suppress Radiation-Induced Senescence and Atherosclerosis

    by Jun-Ichi Abe, Venkata Subrahmanya Kumar Samanthapudi, Weiqing Chen, Jonghae Lee, Ngoc Tuyet Tra, Gilbert F. Mejia, Oanh Hoang, Luis Antonio Rivera, Kun Yuan Chu, Masaki Osawa, et al.

    Background: Ionizing radiation (IR) accelerates atherosclerosis through induction of cellular senescence, DNA damage, defective efferocytosis, and dysregulation of clonal hematopoiesis (CH) drivers. Although low-dose colchicine reduces ischemic cardiovascular events in coronary artery disease, the precise molecular mechanisms underlying its vasculoprotective effects remain incompletely defined, and whether it mitigates radiation-associated vascular injury is unknown. Methods: Bone marrow–derived macrophages (BMDMs) were pretreated with low-dose colchicine and exposed to 2 Gy IR. Molecular effects were assessed by RNA-seq, immunoblotting, and molecular docking. In vivo effects were tested in a partial carotid ligation (PLCL) model using spatial proteomics. Human monocyte-derived macrophages (HMDMs) from thoracic malignancy patients were analyzed before and after radiation therapy (RT). Results: Low-dose colchicine suppressed IR-induced macrophage senescence signaling while preserving NRF2 activity. In a cell-free assay, colchicine directly activated aldehyde dehydrogenase 2 (ALDH2) in a dose-dependent manner (EC 50 1–5 nM), identifying ALDH2 as a direct molecular target of colchicine. Following irradiation, colchicine restored ALDH2, reduced mitochondrial (mt)ROS - dependent p90 ribosomal S6 kinase ( p90RSK ) activation and lipid peroxidation, preserved TET2 and DNMT3A expression, and rescued impaired efferocytosis while preventing nicotinamide adenine dinucleotide (NAD⁺) and adenosine triphosphate (ATP) depletion. These protective effects were ALDH2-dependent, as they were lost with ALDH2 inhibition or depletion and were mimicked by pharmacologic ALDH2 activation. In vivo, colchicine attenuated radiation-induced atherosclerosis and macrophage senescence-associated stemness (SAS). Consistently, macrophages from patients after RT showed reduced ALDH2 with increased mtROS, lipid peroxidation, and senescence. Conclusion: These findings identify ALDH2 as a previously unrecognized molecular target of colchicine that links mitochondrial redox control to suppression of radiation-induced macrophage senescence and atherosclerosis and may contribute to the efficacy of low-dose colchicine in cardiovascular disease.

  • Open Access

    Targeted autonomic testing for radiation‑induced baroreflex failure in head and neck cancer survivors: index case and early program experience

    by Efthymios Triantafyllou, Ingrid González Flores, Cezar Iliescu, Anita Deswal, Elie Mouhayar, Clifton D. Fuller, Efstratios Koutroumpakis

    Radiation‑induced afferent baroreflex failure (R‑ABF) is a highly morbid late effect of neck irradiation in head and neck cancer survivors, and is frequently underrecognized due to nonspecific, fluctuating symptoms. We report an index case in which systematic autonomic evaluation—including adrenergic and cardiovagal assessment—enabled objective diagnosis, severity grading, while physiology‑directed therapy resulted in meaningful symptomatic improvement. The diagnostic trajectory highlights recurrent challenges: prolonged latency from symptom onset to recognition, therapeutic complexity in the setting of cardiovascular comorbidities, and limited access to standardized autonomic testing. In response, we have developed the BARO‑CARE Program, a structured pathway integrating comprehensive autonomic profiling to streamline diagnosis, guide individualized management, and support longitudinal monitoring. This case and early program experience emphasize that even chronic R‑ABF remains therapeutically modifiable when approached with pathophysiologically‑guided care. Programmatic, multidisciplinary models may reduce diagnostic delays and improve outcomes as the survivor population grows.

  • Open Access

    Pericardial Decompression Syndrome Complicated by Left Ventricular Thrombus and Systemic Embolization

    by Francois Haddad, Kara Thompson, Efstratios Koutroumpakis, Nicholas Palaskas, Elie Mouhayar


  • Open Access

    Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

    by Karan Gowda, Medha Gupta, Adrian Aguilar, Carlos Cruz, Amanda Warner, Elizabeth R. Rodriguez, Sairah Ahmed, Branko Cuglievan, Joel Milam, David R. Freyer, et al.

    Cardiac dysfunction is a major morbidity among survivors of adolescent and young adult (AYA) lymphoma. Although high mortality after cardiovascular disease (CVD) diagnosis has been shown in other cancer survivor populations, this has not been investigated in a diverse population of survivors of AYA lymphoma. Therefore, in this study we evaluated survival after a diagnosis of CVD and investigated differences in the CVD‐survival relationship. Demographics, treatment variables, and CVD diagnoses occurring at least 3 months after their lymphoma diagnosis were collected in a diverse population of AYA lymphoma survivors ( N = 825; race/ethnicity: 58.5% White, 26.9% Hispanic, 14.5% Black). Nearly 25% (23.6%; N = 195) had a CVD diagnosis during the median follow‐up time of 9.8 years with the median age at CVD diagnosis being 33.0 years. In Cox models with CVD as a time‐varying covariate, the development of a CVD was highly associated with inferior survival (HR: 7.11, 95% CI: [4.03–12.5]). This adverse CVD‐survival relationship was consistently observed among patient subpopulations; however, the magnitudes of the adverse effect of CVD on survival were most pronounced (HR > 7) among Black and Hispanic patients, NHL survivors, and those with a healthy baseline BMI. Together these findings underscore the need for cardiovascular health surveillance among survivors of AYA lymphoma to potentially mitigate this adverse effect of CVD on survival in this at‐risk population.

  • Open Access

    Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study

    by Efstratios Koutroumpakis, Efthymios Triantafyllou, John Andrew Livingston, Juhee Song, Claire Viguet, Andres Hughes, Savannah V Rauschendorfer, Prince Jeyabal, Theresa A Honey, Joya Chandra, et al.

    Background: Adolescents and young adults (AYAs) with sarcomas often receive high-dose doxorubicin (Dox), but data on early cardiotoxicity in this population are limited. Objectives: To prospectively evaluate early echocardiographic changes in AYAs with sarcoma treated with high-dose Dox. Methods: AYAs (15–39 years) with sarcoma treated at a tertiary cancer centre (2018–22) were prospectively enroled. Echocardiograms were performed at baseline, 1 and 2 years after cancer therapy initiation and interpreted by a single cardiologist. The primary endpoint was a >10% absolute reduction in left ventricular ejection fraction (LVEF), an absolute LVEF 10% decrease in LV wall thickness/dimension (LVWT/D) ratio from baseline. Secondary endpoints included longitudinal changes in cardiac structure, chamber volumes, systolic and diastolic function, and strain. Results: Of 70 patients, 56 completed at least two of three study echocardiograms (median age 22.6 [IQR, 17.6–30.5] years; 41% female, 84% white). Median cumulative Dox dose was 450 (IQR, 370–450) mg/m2; 75% received dexrazoxane. The primary endpoint was met by 44.4% at 1 year and 27.5% at 2 years, driven primarily by LVWT/D ratio decline (37% at 1 year, 25% at 2 years), while significant LVEF decline was observed in 11.1% and 2.5%, respectively. Significant absolute changes at 1 year included LVEF (−2.73 ± 4.3%, P < .001), global longitudinal strain magnitude (−1.37 ± 2.56%, P = .002), septal e′ (−1.75 ± 2.48 cm/s, P < .001), and lateral e′ (−2.78 ± 3.44 cm/s, P < .001), persisting at 2 years. One patient (1.8%) developed ventricular fibrillation and heart failure with reduced ejection fraction, with LVEF recovery within 1 year. Conclusions: Over one-third of AYAs with sarcoma met the primary endpoint at 1 year, with half of these abnormalities persisting at 2 years, primarily driven by LVWT/D ratio reductions. Subclinical changes in strain and diastolic function were observed, reflecting the broad cardiac impact of high-dose Dox in this population.